Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting

被引：0
|
作者：
Doria, Andrea [1 ]
Iaccarino, Luca [1 ]
Bettio, Silvano [1 ]
Frassi, Micol [2 ,3 ]
Andreoli, Laura [2 ,3 ]
Reggia, Rossella [2 ,3 ]
Zen, Margherita [1 ]
Nalotto, Linda [1 ]
Gatto, Mariele [1 ]
Pea, Lara [2 ,3 ]
Punzi, Leonardo [1 ]
Tincani, Angela [2 ,3 ]
机构：
[1] Univ Padua, Padua, Italy
[2] Spedali Civil Brescia, I-25125 Brescia, Italy
[3] Univ Brescia, Brescia, Italy
来源：
ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
671
引用
收藏
页码：S292 / S293
页数：2
相关论文
共 50 条
  • [21] Relationship Between Corticosteroids and Adverse Events in SLE - Data from the Clinical Trial Belimumab in Subjects with Systemic Lupus Erythematosus
    Emamikia, Sharzad
    Gentline, Cidem
    Backheden, Magnus
    Chatzidionysiou, Katerina
    Arnaud, Laurent
    van Vollenhoven, Ronald F.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [22] PREGNANCY IN SLE PATIENTS TREATED WITH BELIMUMAB: EXPERIENCE FROM 3 ITALIAN CENTERS
    Crisafulli, F.
    Gerardi, M. C.
    Moschetti, L.
    Fredi, M.
    Nalli, C.
    Urban, M. L.
    Emmi, G.
    Saccon, F.
    Zen, M.
    Iaccarino, L.
    Doria, A.
    Franceschini, F.
    Andreoli, L.
    Tincani, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 600 - 601
  • [23] Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase Ill clinical trials of belimumab
    Palazzo, L.
    Lindblom, J.
    Cetrez, N.
    Ala, H.
    Parodis, I.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 45 - 45
  • [24] Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina
    Babini, A.
    Cappuccio, A. M.
    Caprarulo, C.
    Casado, G.
    Eimon, A.
    Figueredo, H.
    Garcia, M. A.
    Magri, S.
    Mannucci, P.
    Perez Rodriguez, S.
    Pons-Estel, B. A.
    Velozo, E. J.
    Iglesias-Rodriguez, M.
    Streger, G.
    LUPUS, 2020, 29 (11) : 1385 - 1396
  • [25] SLE Patients with No Organ Damage Might Benefit More from Belimumab Treatment
    Parodis, Ioannis
    Emamikia, Sharzad
    Gomez, Alvaro
    Chatzidionysiou, Katerina
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [26] PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB
    Palazzo, L.
    Lindblom, J.
    Cetrez, N.
    Ala, H.
    Parodis, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1088 - 1088
  • [27] Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies
    Sheikh, Saira
    Withrop, Kevin
    Yazdany, Jinoos
    Navarra, Sandra
    Atsuma, Tatsuya
    Curtis, Paula
    Olaiz, Jose Miyar
    Henning, Christine
    Levy, Roger A.
    Stohl, William
    Wallace, Daniel
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2958 - 2960
  • [28] EFFECT OF BELIMUMAB ON CLINICAL PROFILES AND DAILY LIVING SCORE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Ishizuka, T.
    Fujioka, K.
    Tangiku, M.
    Tani, H.
    Maeda, A.
    Kato, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1471 - 1471
  • [29] Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
    Zahi Touma
    Amyn Sayani
    Christian A. Pineau
    Isabelle Fortin
    Mark Matsos
    George A. Ecker
    Andrew Chow
    Sandra Iczkovitz
    Rheumatology International, 2017, 37 : 865 - 873
  • [30] Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study
    Touma, Zahi
    Sayani, Amyn
    Pineau, Christian A.
    Fortin, Isabelle
    Matsos, Mark
    Ecker, George A.
    Chow, Andrew
    Iczkovitz, Sandra
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (06) : 865 - 873
12345